InvestorsHub Logo
icon url

KCSVEN

07/08/13 6:23 PM

#9967 RE: Whalatane #9965

IF GIA for Anchor then there is more dilution/money raising coming, this smacks of a smaller partnership...Elan? with no money up front and shared costs and salesforce as they raised about half what is needed for Anchor launch.

If GIA for Anchor, this raise makes no sense as they need to go back and do it again, unless they are getting another loan....

I think it nixes any chance of someone buying in 25% of Vascepa but when you think about it, Vascepa is the only asset they have, taking money for a percent now, at beginning of Anchor launch, is like selling 25% of the company way below future value. So they might get 500 million for 25% and a combined sales force...no way anyone pays them a billion....so why take money up front?

So I think, to me, this leads way more towards a partnership, but a unique deal that involves no money up front, a sales force and royalties to them based on sales. I KNOW they would need 300 million to launch Anchor GIA, maybe more but at least 300 million and they have increased interest payments coming and the increased REDUCE IT cost...

Nope GIA can only be possible if they have some other financing...the financing today says GIA is out and up front payment for partnership is out. IF this is all the financing those two things are fact...if there is more financing then GIA can be on the table...but saying the raise today means GIA makes no sense since they don;t have enough money to do that after this raise.

I don't think people realize how much a PROPER launch that needs 1200 sales reps and needs to reach all PCP's and 40 million people will cost, I tell you if today's raise is it Anchor will be slow to ramp up...way to slow

icon url

stangish

07/08/13 6:34 PM

#9974 RE: Whalatane #9965

From Amarins own Prospectus today:

"Use of proceeds
We intend to use the net proceeds from this offering to continue the commercial launch of Vascepa® (icosapent ethyl) capsules in the MARINE indication, prepare for and commercially launch Vascepa in the ANCHOR indication, if approved, advance our REDUCE-IT cardiovascular outcomes trial, and for general corporate and working capital purposes. See “Use of Proceeds.”"

IMO Amarin wants a major premium. NO company is going to currently pay this premium without 1 of the following happening:

1) MAJOR uptake in sales.

AND/OR

2) Successful reduce it trial